Advances in the clinical application of neoadjuvant immunotherapy for resectable locally advanced esophageal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20241009-00052

Abstract

Abstract:

Esophageal cancer cases in China account for more than 50% of the world， among which approximately 90% are histological subtypes of esophageal squamous cell carcinoma. Over 50% of esophageal cancer patients are initially diagnosed at locally advanced or advanced stages. The R0 resection rate with surgical treatment alone is relatively low， and local recurrence and distant metastasis are prone to occur， resulting in a low 5-year survival rate. Recent research has focused on neoadjuvant therapy for esophageal cancer， but the most effective form of such therapy remains undetermined. Immunotherapy is currently the most active research field in tumor treatment. Further exploration of the treatment model combing immunotherapy with neoadjuvant chemotherapy or chemoradiotherapy is expected to improve the therapeutic effect and survival benefit in patients with locally advanced resectable esophageal squamous cell carcinoma.

Key words: Esophageal squamous cell carcinoma, Neoadjuvant therapy, Immunotherapy

Sun Yujiao, Yu Meili, Ma Wenjing, Sun Longmei, Zhu Zhaofeng, Zheng Yuanyuan. Advances in the clinical application of neoadjuvant immunotherapy for resectable locally advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(5): 309-314.

References 45

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Zhang R, Lau LHS, Wu PIC, et al. Endoscopic diagnosis and treatment of esophageal squamous cell carcinoma[J]. Methods Mol Biol, 2020, 2129: 47-62. DOI: 10.1007/978-1-0716-0377-2_5. pmid: 32056169
[3]	An L, Li M, Jia Q. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma[J]. Mol Cancer, 2023, 22(1): 140. DOI: 10.1186/s12943-023-01839-2.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管鳞状细胞癌新辅助放射治疗专家共识[J]. 国际肿瘤学杂志, 2023, 50(3): 129-137. DOI: 10.3760/cma.j.cn371439-20230217-00027.
[5]	Demarest CT, Chang AC. The landmark series: multimodal therapy for esophageal cancer[J]. Ann Surg Oncol, 2021, 28(6): 3375-3382. DOI: 10.1245/s10434-020-09565-5. pmid: 33629251
[6]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590.
[7]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南(2023年版)[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397. DOI: 10.3760/cma.j.cn371439-20230612-00077.
[8]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
[9]	Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836. pmid: 34519801
[10]	Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471. DOI: 10.1016/S0140-6736(17)31827-5.
[11]	Yagi T, Baba Y, Ishimoto T, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer[J]. Ann Surg, 2019, 269(3): 471-478. DOI: 10.1097/SLA.0000000000002616. pmid: 29206673
[12]	O'Donnell JS, Hoefsmit EP, Smyth MJ, et al. The promise of neoadjuvant immunotherapy and surgery for cancer treatment[J]. Clin Cancer Res, 2019, 25(19): 5743-5751. DOI: 10.1158/1078-0432.CCR-18-2641. pmid: 31040150
[13]	Cui K, Hu S, Mei X, et al. Innate immune cells in the esophageal tumor microenvironment[J]. Front Immunol, 2021, 12: 654731. DOI: 10.3389/fimmu.2021.654731.
[14]	Zheng Y, Chen Z, Han Y, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment[J]. Nat Commun, 2020, 11(1): 6268. DOI: 10.1038/s41467-020-20019-0.
[15]	Yang W, Xing X, Yeung SJ, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(1): e003497. DOI: 10.1136/jitc-2021-003497.
[16]	Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3): 197-218. DOI: 10.1038/s41573-018-0007-y. pmid: 30610226
[17]	Chen X, Zhang W, Qian D, et al. Chemoradiotherapy-induced CD4⁺ and CD8⁺ T-cell alterations to predict patient outcomes in esophageal squamous cell carcinoma[J]. Front Oncol, 2019, 9: 73. DOI: 10. 3389/fonc.2019.00073. pmid: 30828566
[18]	Wang Y, Liu ZG, Yuan H, et al. The reciprocity between radiotherapy and cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(6): 1709-1717. DOI: 10.1158/1078-0432.CCR-18-2581. pmid: 30413527
[19]	Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Signal Transduct Target Ther, 2022, 7(1): 258. DOI: 10.1038/s41392-022-01102-y.
[20]	Zhang W, Pang Q, Zhang X, et al. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor[J]. Cancer Sci, 2017, 108(4): 590-597. DOI: 10.1111/cas.13197.
[21]	Lim SH, Hong M, Ahn S, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer[J]. Eur J Cancer, 2016, 52: 1-9. DOI: 10.1016/j.ejca.2015.09.019. pmid: 26623522
[22]	Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547): 373-377. DOI: 10.1038/nature14292.
[23]	Gong J, Le TQ, Massarelli E, et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination[J]. J Immunother Cancer, 2018, 6(1): 46. DOI: 10. 1186/s40425-018-0361-7.
[24]	Wen J, Fang S, Hu Y, et al. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma[J]. EBioMedicine, 2022, 86: 104371. DOI: 10.1016/j.ebiom. 2022.104371.
[25]	Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade[J]. Science, 2016, 354(6316): 1160-1165. DOI: 10. 1126/science.aaf2807. pmid: 27789795
[26]	Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714. DOI: 10.1136/bmj-2021-068714.
[27]	Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288.e3. DOI: 10.1016/j.ccell.2022.02.007.
[28]	Shang X, Zhao G, Liang F, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage Ⅲ) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-Ⅱ trial (Keystone-001)[J]. Ann Transl Med, 2022, 10(4): 229. DOI: 10.21037/atm-22-513.
[29]	Jing SW, Zhai C, Zhang W, et al. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: a propensity score matching[J]. Front Immunol, 2022, 13: 970534. DOI: 10.3389/fimmu.2022.970534.
[30]	Yang Y, Liu J, Liu Z, et al. Two-year outcomes of clinical N_2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study[J]. J Thorac Cardiovasc Surg, 2024, 167(3): 838-847.e1. DOI: 10.1016/j.jtcvs. 2023.08.056.
[31]	Zhang B, Zhao H, Wu X, et al. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer[J]. Front Immunol, 2023, 14: 1066527. DOI: 10.3389/fimmu.2023.1066527.
[32]	Yang P, Zhou X, Yang X, et al. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study[J]. World J Surg Oncol, 2021, 19(1): 333. DOI: 10.1186/s12957-021-02446-5.
[33]	Zhang Z, Ye J, Li H, et al. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase 2 trial[J]. Front Immunol, 2022, 13: 1031171. DOI: 10.3389/fimmu.2022.1031171.
[34]	Lv H, Huang C, Li J, et al. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma[J]. Front Immunol, 2022, 13: 1100750. DOI: 10.3389/fimmu.2022.1100750.
[35]	Chen X, Xu X, Wang D, et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial[J]. J Immunother Cancer, 2023, 11(2): e005830. DOI: 10. 1136/jitc-2022-005830.
[36]	Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. DOI: 10.1016/S1470-2045(23)00108-0. pmid: 37080222
[37]	Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase Ⅱ study (TD-NICE)[J]. Int J Surg, 2022, 103: 106680. DOI: 10.1016/j.ijsu.2022.106680.
[38]	He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma[J]. Oncologist, 2022, 27(1): e18-e28. DOI: 10.1093/oncolo/oyab011.
[39]	Zhang G, Yuan J, Pan C, et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial[J]. EBioMedicine, 2023, 90: 104515. DOI: 10.1016/j.ebiom.2023.104515.
[40]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[41]	Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial[J]. JAMA Surg, 2021, 156(8): 721-729. DOI: 10.1001/jamasurg.2021.2373. pmid: 34160577
[42]	Chen R, Liu Q, Li Q, et al. A phase Ⅱ clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)[J]. EClinicalMedicine, 2023, 62: 102118. DOI: 10.1016/j.eclinm.2023. 102118.
[43]	Jiang N, Zhang J, Guo Z, et al. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ⅰb clinical trial[J]. J Immunother Cancer, 2024, 12(1): e008229. DOI: 10.1136/jitc-2023-008229.
[44]	Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144: 232-241. DOI: 10. 1016/j.ejca.2020.11.039. pmid: 33373868
[45]	Park SY, Hong MH, Kim HR, et al. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma[J]. J Thorac Dis, 2020, 12(11): 6426-6434. DOI: 10.21037/jtd-20-1088. pmid: 33282345